The findings shed light on the dual roles of WISP2 in HCC, suggesting that WISP2 up-regulation combined with HMGB1 inhibition may serve as an effective therapeutic strategy for better prognosis in HCC. This evidence concerns the gene CCN5 and hepatocellular carcinoma.